Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.58 |
| ▸ | BIRC2 | Q13490 | 5/20 | 0.35 |
| ▸ | XIAP | P98170 | 1/20 | 0.35 |
| ▸ | BIRC3 | Q13489 | 1/20 | 0.35 |
| ▸ | STAT6 | P42226 | 5/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | STAT5A | P42229 | 1/20 | 0.34 |
| ▸ | STAT5B | P51692 | 1/20 | 0.34 |
| ▸ | NTSR2 | O95665 | 2/20 | 0.34 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.34 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL57417 | 1.00 | TUBB1 (0.58) | TUBB1BIRC2XIAPBIRC3STAT6 | |
| SCHEMBL14185880 | 1.00 | TUBB1 (0.58) | TUBB1BIRC2XIAPBIRC3STAT6 | |
| SCHEMBL58688 | 0.94 | TUBB1 (0.59) | TUBB1BIRC2XIAPBIRC3STAT6 | |
| SCHEMBL4368595 | 0.94 | TUBB1 (0.59) | TUBB1BIRC2XIAPBIRC3STAT6 | |
| SCHEMBL58756 | 0.92 | TUBB1 (0.61) | TUBB1BIRC2XIAPBIRC3STAT6 | |
| SCHEMBL57941 | 0.92 | TUBB1 (0.61) | TUBB1BIRC2XIAPBIRC3STAT6 | |
| SCHEMBL57912 | 0.92 | TUBB1 (0.61) | TUBB1BIRC2XIAPBIRC3STAT6 | |
| SCHEMBL4366593 | 0.92 | TUBB1 (0.61) | TUBB1BIRC2XIAPBIRC3STAT6 | |
| SCHEMBL4371788 | 0.92 | TUBB1 (0.57) | TUBB1BIRC2XIAPBIRC3STAT6 | |
| SCHEMBL14273012 | 0.90 | TUBB1 (0.60) | TUBB1BIRC2XIAPBIRC3STAT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309938-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO., LTD. (JP) | 2012-12-06 | — | — | US | disclosed |
| EP-2374454-A1 | Hemiasterlin derivatives and uses thereof in the treatment of cancer | Eisai R&D Management Co., Ltd. (JP) | 2011-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309938-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | DHCR7, HSD17B7, HCCS | TUBB1 1330/4885BIRC2 2736/4885XIAP 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.